Evidence map›Paper›PMID 38517589›Full record

ReviewJournal of physiology and biochemistry2024

MicroRNA-126 (MiR-126): key roles in related diseases.

Li Liao, Yan Tang, Yanping Zhou, Xianglin Meng, Bo Li, Xiaochun Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of physiology and biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Mechanistic insight into the role of cardiac-enriched microRNAs in diabetic heart injury.American journal of physiology. Heart and circulatory physiology · 2025
    Review
  9. Review
  10. Review
  11. MicroRNA Gets a Mighty Award.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Li LiaoThe Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, 644000, China. liaoli19872021@163.com.
Yan TangThe Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, 644000, China.
Yanping ZhouThe Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, 644000, China.
Xianglin MengThe Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, 644000, China.
Bo LiThird Affiliated Hospital of Chengdu Medical College-Chengdu Pidu District People's Hospital, Chengdu, 611700, China.
Xiaochun ZhangThe Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, 644000, China. xcz2008xc@163.com.
Sichuan University · CNWest China Hospital of Sichuan University · CNChengdu Medical College · CNSecond People’s Hospital of Yibin · CN

Funding

Chengdu Medical Research Project NO.2022655Sichuan Hospital Association Young Pharmacist Research Special Fund Project NO.22047Sichuan Provincial Medical Youth Innovation Research Project NO.Q20027
6 · The paper itself

Abstract

In eukaryotes such as humans, some non-coding single-stranded RNAs (ncRNAs) help to regulate the pre- and post-transcriptional expression of certain genes, which in turn control many important physiological processes, such as cell proliferation, distinctions, invasion, angiogenesis, and embryonic development. microRNA-126 is an important member of these miRNAs that can be directly or indirectly involved in the control of angiogenesis. Recently, numerous studies have expounded that microRNA-126 can inhibit or promote angiogenesis as well as attenuate inflammatory responses through complex molecular mechanisms. As such, it serves as a biomarker or potential therapeutic target for the prediction, diagnosis, and treatment of relevant diseases. In this review, we present the advancements in research regarding microRNA-126's role in the diagnosis and treatment of related diseases, aiming to provide innovative therapeutic options for the diagnosis and treatment of clinically relevant diseases.

Indexed as

MicroRNAsAnimalsHumansNeoplasmsNeovascularization, PathologicMicroRNAsMIRN126 microRNA, humanCancerCardiovascular diseaseCerebrovascular diseasemicroRNA-126Retinal diseaseSepsisTumor

Identifiers

PMID38517589
OpenAlexW4393093154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.